Sanofi (Euronext:SAN; NASDAQ:SNY) has expanded its toolbox for developing multispecific modalities through a licensing deal with Biomunex Pharmaceuticals (Paris, France).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,